论文部分内容阅读
目的:评价奥卡西平(OXC)和卡马西平(CBZ)治疗部分性癫痫发作疗效和安全性的差异。方法:在Cochrane图书馆、PubMed、中国医院数字图书馆上检索OXC和CBZ单药治疗部分性癫痫发作的随机对照试验(RCT),采用Meta分析专用软件RevMan 5.0.0进行系统评价。结果:共纳入5个RCT,454例部分性癫痫患者,其中A级文献3篇,C级2篇;Meta分析结果显示,OXC组和CBZ组治疗部分性癫痫的总控制率相当,2组比较差异无统计学意义[RR1.09,95%CI(0.73,1.64)];OXC组不良反应(ADR)发生率低于CBZ组[RR0.61,95%CI(0.41,0.91)];OXC组严重ADR退出率也低于CBZ组(RR0.51,95%CI(0.28,0.92))。结论:现有证据表明,OXC治疗部分性癫痫发作疗效并不优于CBZ,但前者安全性更好。
Objective: To evaluate the efficacy and safety of oxaliplatin (OXC) and carbamazepine (CBZ) in the treatment of partial seizures. METHODS: Randomized controlled trials (RCTs) of OXC and CBZ monotherapy for partial seizures were searched at the Cochrane Library, PubMed and Chinese Hospital Digital Library. The review was conducted using RevMan 5.0.0, a meta-analysis software. Results: There were 5 RCTs and 454 patients with partial epilepsy, of whom 3 were Grade A and 2 were C; 2 Meta-analysis showed that the total control rate of partial epilepsy was the same in OXC and CBZ groups, The difference was not statistically significant [RR1.09,95% CI (0.73,1.64)]; OXC group adverse reaction (ADR) incidence was lower than the CBZ group [RR0.61,95% CI (0.41,0.91)]; OXC group The rate of withdrawal from severe ADR was also lower than that of the CBZ group (RR 0.51, 95% CI 0.28, 0.92). Conclusion: The available evidence shows that OXC is not superior to CBZ in the treatment of partial seizures, but the former is more safe.